India Pharma Outlook Team | Thursday, 24 September 2026
Claude AI uncovers a novel enzyme system with CRISPR-like features, delivering Anthropic’s first public result from its biology research program.
The company reports that its Claude model analyzed large DNA databases and identified an unusual architecture built around a reverse transcriptase.
Anthropic names the system array-associated reverse transcriptases, or ART. ART contains repeating DNA sequences that resemble patterns found in CRISPR.
While researchers had previously identified the underlying enzyme, Claude recognizes the broader functional system, including an array of non-coding DNA sequences and an additional protein of unknown function.
The finding arrives days after Anthropic establishes a wet lab in the San Francisco Bay Area and expands its work in life sciences beyond purely computational approaches.
Claude examines extensive DNA databases and detects a distinctive system organized around a reverse transcriptase. This enzyme copies RNA into DNA. Anthropic designates the complete arrangement as array-associated reverse transcriptases, or ART.
ART features repeating DNA sequences that mirror patterns observed in CRISPR systems. The company notes that earlier studies had already described the reverse transcriptase itself. Claude, however, identifies critical elements of the larger architecture that researchers had overlooked.
These include an array of non-coding DNA sequences and a second protein whose function remains unknown. The distinction marks a shift. Most AI applications in biology focus on predicting protein structures or designing individual molecules. Here Claude surfaces an entire functional system that human analysis had not fully assembled.
Key elements of the discovery:
Also Read: 10 AI Innovations Transforming Drug Discovery in 2026
The ART finding coincides with Anthropic’s move into experimental biology. The company quietly sets up a wet lab in the San Francisco Bay Area. This step extends its ambitions in life sciences and drug-related research beyond computer-based modeling. The combination of large-scale DNA analysis by Claude and new laboratory capacity positions Anthropic to pursue both computational discovery and experimental validation.
Anthropic places the ART result in the public domain at a moment when multiple organizations compete to apply advanced AI to biological problems. The announcement demonstrates that the company’s models can move past prediction tasks and recognize higher-order biological organization.
Highlighting a system that integrates a known enzyme with previously unconnected DNA features, Anthropic signals its intent to operate in the same scientific space as other leading AI and biotech groups.
The discovery therefore serves two purposes. It adds a concrete scientific observation to the record and simultaneously marks Anthropic’s formal entry into system-level biological discovery. Researchers will now examine whether ART systems perform functions analogous to CRISPR or open other avenues for genome-related research.
.jpg)
